Oklahoma Oncology & Hematology P.C. v. US Oncology, Inc.

2007 OK 12, 160 P.3d 936, 2007 Okla. LEXIS 17, 2007 WL 798961
CourtSupreme Court of Oklahoma
DecidedMarch 15, 2007
Docket102,673, 102,612
StatusPublished
Cited by127 cases

This text of 2007 OK 12 (Oklahoma Oncology & Hematology P.C. v. US Oncology, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Oklahoma primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Oklahoma Oncology & Hematology P.C. v. US Oncology, Inc., 2007 OK 12, 160 P.3d 936, 2007 Okla. LEXIS 17, 2007 WL 798961 (Okla. 2007).

Opinion

TAYLOR, J.

T1 The basic question in this appeal and the consolidated original action is whether the district court erred in sending all claims in this suit to arbitration. We find the district court erred in compelling arbitration and reverse the arbitration order. We remand this case to the district court with instructions.

I. The Proceedings Below

12 The following are basic facts gleaned from the district court filings and the arguments in this Court 1 Plaintiff/appellant, Oklahoma Oncology & Hematology P.C., d/b/a Cancer Care Associates (CCA), is an Oklahoma professional corporation of Oklahoma-licensed physicians who engage in the practice of medical oncology, hematology, and radiation oncology throughout the state of Oklahoma. CCA has more than sixty full-time, part-time, and contract physicians, and it has offices in Tulsa, Oklahoma City, Norman, Bartlesville McAlester, Muskogee, Pryor, Enid, Vinita, and Stillwater.

13 Defendant/appellee AOR Management Company of Oklahoma, Inc. (AOR-OK) is a Delaware corporation incorporated in 1995 to provide business management services in Oklahoma to CCA. AOR-OK was a wholly-owned subsidiary of American Oncology Resources, Inc. (AOR) until it became a wholly-owned subsidiary of defendant/appellee U.S. Oncology, Inc. (USON) in 1999. 2 Since its inception, AOR-OK has maintained its corporate office in the offices of CCA in Tulsa, Oklahoma.

T4 This controversy has its origin in a business transaction that occurred in 1995, whereby AOR-OK became the business manager for the oncology medical practices of the CCA physicians The transactional documents executed in March, 1995, included the Management Services Agreement (MSA) between CCA and Oncology and Hematology Management Partnership, a Texas General Partnership (the Texas partnership) and a Purchase Agreement executed by AOR, AOR-OK, CCA, Oklahoma Oncology & Hematology P.C., and more than fifteen physi-clans.

15 The MSA is the central contract in this controversy. The MSA was executed by only one person, Alan M. Keller, M.D., a CCA physician. Dr. Keller executed the agreement both on behalf of the Texas general partnership and on behalf of CCA. 3 *941 Even though it is a contract between CCA and the Texas partnership, the MSA provided for AOR to succeed to all the rights and obligations of the Texas partnership thereunder, it directed AOR to assign its rights and obligations under the MSA to AOR-OK, and it designated AOR-OK as the business manager for CCA 4

T6 The MSA prescribed the duties and obligations of CCA and AOR-OK for the business management of the oncology medical practices of the CCA physicians. The MSA has a forty-year term with automatic renewal every five years thereafter. The MSA fixed AOR-OK's business management fees for the first five years at a "monthly fee" in the amount equal to the "fixed amount" plus seven percent of the adjusted gross revenue. The "fixed amount" for the first sixty months ranged from $325,890 to $359,013 under the schedule in the MSA. However, the "fixed amount" was increased by several amendments to the MSA. The first amendment was in January of 1997 and the last was in October of 1999. Each amendment was in writing and executed on behalf of AOR-OK and CCA. After the first five years, the MSA provided for a "monthly fee" equal to 24.7% of the adjusted gross revenue. 5

T7 The working relationship between CCA and AOR-OK during the first five years apparently disintegrated after USON became the parent corporation of AOR-OK. According to CCA, USON has taken control of CCA's administrative and financial business, its money and accounts, and its books and records. - On January 26, 2005, CCA notified AOR-OK that it considered the MSA to be illegal, against public policy, and void ab initio under Oklahoma law. Two days later, on January 28, 2005, AOR-OK filed an arbitration complaint asking that the business management fee provisions in the MSA be reformed.

T8 In the arbitration complaint, AOR-OK alleged that 1) macro-economic changes in the cancer care industry during the past several years resulted in a substantially lower business management fee for AOR-OK, 2) CCA and AOR-OK have been unable to agree to any changes in the business management fee since 1999, and 3) AOR-OK resigned itself to fulfilling the MSA for substantially less profit than had been anticipated. It further alleged that the change in reimbursement rates in the Medicaid Modernization Act of 2003 directly impacts the amount of the business management fee in the MSA.

T9 The arbitration complaint referred to section 7.2(d) of the MSA as authorizing arbitration for the purpose of rewriting the business management fee provisions in the MSA. Section 7.2(d) provides for the parties to negotiate in good faith concerning a new service arrangement or a new basis for compensation as may be necessary due to change in Medicare/Medicaid law, state law or change in any third party reimbursement system; and if the parties cannot agree to a new service arrangement or basis for compensation, it provides for the matter to be sent to binding arbitration.

*942 110 The relief sought in the arbitration complaint is "a judgment that would reform the terms of the MSA such that AOR Management [AOR-OK] would be compensated at a level that approximates as closely as possible its economic position that it was in prior to changes caused by the MMA [Medicaid Modernization Act]." The arbitration complaint also seeks "costs and expenses, including reasonable attorneys' fees, for prosecution of this proceeding, as well as any further relief to which it justly may be entitled."

T11 CCA did not answer the arbitration complaint. Instead, it filed suit in the Tulsa County District Court on February 14, 2005. The amended petition asserts that the MSA is contrary to established public policy in that it allows AOR-OK to engage in the unlicensed and unauthorized practice of medicine, to split patient revenues, and to exert dominion and control over CCA's medical practice and financial affairs. It further asserts that USON is treating CCA as if it is a wholly-owned subsidiary of USON by exercising dominion and control over CCA's entire business. The amended petition asks the district court to declare that the MSA was void ab imitio and unenforceable and that there is no valid contract between the parties. It also sought a stay of arbitration and an award of compensatory and punitive damages for breach of contract, fraud and deceit, conversion, and misappropriation and embezzlement, together with interest, costs, and attorney fees against both AOR-OK and USON.

112 CCA also sought an emergency stay of AOR-OK's arbitration proceeding until the district court decides whether the MSA is contrary to Oklahoma law and public policy and void ab initio. The district court stayed the arbitration.

T13 Neither AOR-OK nor USON answered the district court petition. They filed a motion to lift the stay and to compel arbitration.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Greenfield v. Circustrix, LLC
2025 OK CIV APP 19 (Court of Civil Appeals of Oklahoma, 2025)
EXENCIAL WEALTH ADVISORS v. MORGAN STANLEY SMITH BARNEY
2024 OK CIV APP 29 (Court of Civil Appeals of Oklahoma, 2024)
Donovin Last v. M-I, L.L.C.
E.D. California, 2024
WATTS v. BELMAR NORTH HOA
2023 OK CIV APP 22 (Court of Civil Appeals of Oklahoma, 2023)
MOORE v. BOB HOWARD GERMAN IMPORTS
531 P.3d 657 (Court of Civil Appeals of Oklahoma, 2023)
MAGEL v. NUVEEN
2023 OK CIV APP 13 (Court of Civil Appeals of Oklahoma, 2023)
SUBURBAN REALTY CO. v. CANTLEY
2021 OK CIV APP 27 (Court of Civil Appeals of Oklahoma, 2021)
HOWELL'S WELL SERVICE v. FOCUS GROUP ADVISORS
2021 OK 25 (Supreme Court of Oklahoma, 2021)
RCB BANK v. STITT
2022 OK CIV APP 3 (Court of Civil Appeals of Oklahoma, 2021)
Burgess v. Johnson
Tenth Circuit, 2020
SIGNATURE LEASING LLC v. BUYER'S GROUP LLC
2020 OK 50 (Supreme Court of Oklahoma, 2020)
WILLIAMS v. TAMKO BUILDING PRODUCTS INC
2019 OK 61 (Supreme Court of Oklahoma, 2019)
Lucky Duck Drilling, LLC v. Am. Oil for Americans, LP
443 P.3d 1144 (Court of Civil Appeals of Oklahoma, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
2007 OK 12, 160 P.3d 936, 2007 Okla. LEXIS 17, 2007 WL 798961, Counsel Stack Legal Research, https://law.counselstack.com/opinion/oklahoma-oncology-hematology-pc-v-us-oncology-inc-okla-2007.